Novo Nordisk AS (XTER:NOV)
€ 99.51 -3.09 (-3.01%) Market Cap: 442.81 Bil Enterprise Value: 440.41 Bil PE Ratio: 35.07 PB Ratio: 27.45 GF Score: 91/100

Q4 2022 Novo Nordisk A/S Earnings Call Transcript

Feb 01, 2023 / 12:00PM GMT
Release Date Price: €63 (-0.57%)
Operator

Good day and thank you for standing by. Welcome to the Q4 2022 Novo Nordisk A/S Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lars Fruergaard Jorgensen, CEO. Please go ahead.

Lars Fruergaard Jorgensen;S;President
Novo Nordisk A;CEO & Member of Management Board

/- -

Thank you, operator. Welcome to this Novo Nordisk Earnings call for the full year of 2022 and the outlook for 2023. My name is Lars Fruergaard Jorgensen, and I'm the CEO of Novo Nordisk. With me today, I have Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla Sylvest;, Executive Vice President and Head of North America Operations, Doug Langa; Executive Vice President and Head of Development, Martin Holst Lange; and finally, Chief Financial Officer Karsten Munk Knudsen. All of us would be available for the Q&A session.

Today's announcement and the slides for this call are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot